Effect of piperine supplement in patients with non alcoholic fatty liver disease

Phase 3

Recruiting

Conditions: on-Alcoholic Fatty Liver Disease.
Fatty (change of) liver, not elsewhere classified
K76.0

Registration Number: IRCT20180802040678N2

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 64

Inclusion Criteria

Grade 2 and 3 non-alcoholic fatty liver
ALT levels upper than 1.5 times the normal upper limit

Exclusion Criteria

Chronic liver disease, diabetes, malignancy, hereditary diseases that affect the liver such as iron and copper storage disorder, untreated hypothyroidism, autoimmune disease, pregnancy, lactation, alcoholic fatty liver disease, consumption Alcohol, hepatitis
Hypolipidemic and anti-inflammatory agents
Bariatrics surgery in last year
43/5000Heavy diet to lose weight in the last 3 months
Increase in fatty liver grade grade based on ultrasonographic findings during the study period
Weight loss more than 10% during the study
Discontent to continuation the study
Not taking more than 10% of supplement

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fattly Liver Grading. Timepoint: Before and after intervention. Method of measurement: Ultrasonography.;Quality of Life. Timepoint: Before and after intervention. Method of measurement: SF-36, CLDQ, and Disease Symptom Index 2.0 questionnaires.;Anthropometric indices. Timepoint: Before and after intervention. Method of measurement: Body weight and Body Mass Index.;Biochemical parameters. Timepoint: Before and after intervention. Method of measurement: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Bilirubin Total and Direct, Fasting Blood Suger, Triglyceride, LDL, HDL, VLDL, Hs-CRP, Total Cholesterol, Albumin, Count Blood Cells, HbA1C, HOMA-IR, Fecal Calprotectin.

Secondary Outcome Measures